Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


18. F. Duran Reynals, "Exaltation de l'Activité du Virus Vaccinal Par les Extraits de Certains Organes," Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie. 99, 6–7 (1928).

19. A. Claude and F. Duran-Reynals, "Chemical Properties of the Non-purified Spreading Factor from Testicle," J Exp Med. 65 (5), 661–670 (1937).

20. F. Duran-Reynals, "A Spreading Factor in Certain Snake Venoms and its Relation to their Mode of Action," J. Exp. Med. 69 (1), 69–81 (1939).

21. K. Meyer, "Hyaluronidases," in: The Enzymes, P.D. Boyer Ed., (Academic Press, New York, NY, 3rd edition, 1971), pp. 307–320.

22. K. Meyer, P. Hoffman, and A. Linker, "Hyaluronidases," in The Enzymes, P.D. Boyer, H. Lardy, and K. Myrback, Eds. (Academic Press, New York, NY, 2nd ed., 1960), pp.447–460.

23. R.G. Williams, "The Effects of Continuous Local Injection of Hyaluronidase on Skin and Subcutaneous Tissue in Rats," Anat. Rec. 122 (3), 349–361 (1955).

24. K. Pillwein et al., "Hyaluronidase Additional to Standard Chemotherapy Improves Outcome for Children with Malignant Brain Tumors," Cancer Lett. 131 (1), 101–108 (1998).

25. A.H. Eberhart, C.R. Weiler, and J.C. Erie, "Angioedema Related to the Use of Hyaluronidase in Cataract Surgery," Am. J. Ophthalmol. 138 (1), 142–143 (2004).

26. R.A. Harrison and S.J. Gaunt, "Multiple Forms of Ram and Bull Sperm Hyaluronidase Revealed by Using Monoclonal Antibodies," J. Reprod. Fertil. 82 (2), 777–785 (1988).

27. R.A. Harrison, "Hyaluronidase in Ram serum. Quantitative Determination and Isolation of Multiple Forms," Biochem J. 252 (3), 865–874 (1988).

28. H.Tint and R. Bogash (American Home Products), "Hyaluronidase," US Patent 2676139, Sept. 1, 1950.

29. H.E. Alburn et al. (American Home Products), "Stabilized Hyaluronidase Solution Containing Calcium Chloride, US Patent 2795529, June 11, 1957.

30. C.L. Borders and M.A. Raftery, "Purification and Partial Characterization of Testicular Hyaluronidase," J. Biol. Chem. 243 (13), 3756–3762 (1968).

31. W.F. Lathrop et al., "cDNA Cloning Reveals the Molecular Structure of a Sperm Surface Protein, PH-20, Involved in Sperm-egg Adhesion and the Wide Distribution of its Gene among Mammals,"J. Cell. Biol. 111 (6 Pt 2), 2939–2949 (1990).

32. M. Gmachl and G. Kreil, "Bee Venom Hyaluronidase is Homologous to a Membrane Protein of Mammalian Sperm," Proc. Natl. Acad. Sci. USA 90 (8), 3569–3573 (1993).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
75%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here